Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Higher thrombin activatable fibrinolysis inhibitor levels are associated with inflammation in attack-free familial Mediterranean fever patients.
[familial mediterranean fever]
Coagulation
abnormalities
have
been
reported
in
familial
Mediterranean
fever
(
FMF
)
patients
with
amyloidosis
and
nephrotic
syndrome
;
but
there
is
not
enough
data
about
the
continuity
of
the
thrombogenic
activity
in
FMF
patients
in
clinical
remission
.
The
purpose
of
this
study
was
to
assess
thrombin
activatable
fibrinolysis
inhibitor
(
TAFI
)
levels
and
its
relationship
with
fibrinolytic
activity
and
also
evaluate
relationships
between
mutations
and
clinical
signs
in
attack-free
patients
without
amyloidosis
.
Seventy
-
nine
FMF
patients
and
40
healthy
adults
were
included
.
The
study
group
was
divided
into
five
groups
as
follows
:
first
group
,
homozygote
M
694
V
;
second
group
,
homozygote
M
680
I
;
third
group
,
M
694
V
in
one
allele
,
the
other
allele
have
other
mutations
or
not
;
fourth
group
,
other
mutations
;
and
fifth
group
,
no
mutation
.
Serum
TAFI
levels
were
significantly
increased
in
patients
compared
with
healthy
individuals
(
116
.
64
 
±
 
21
.
8
vs
.
78
.
48
 
±
 
19
.
7
 
μg
/
mL
,
p
 
<
 
0
.
001
)
and
a
positive
correlation
was
detected
between
TAFI
antigen
level
and
erythrocyte
sedimentation
rate
and
C-
reactive
protein
levels
(
r
 
=
 
0
.
247
,
p
 
=
 
0
.
029
and
r
 
=
 
0
.
252
,
p
 
=
 
0
.
032
,
respectively
)
.
Mean
fibrinogen
and
TAFI
levels
were
significantly
higher
in
Group
1
than
the
other
groups
(
p
 
=
 
0
.
04
and
p
 
=
 
0
.
001
,
respectively
)
and
in
Group
3
it
was
higher
than
Groups
2
,
4
and
5
(
p
 
=
 
0
.
04
and
p
 
=
 
0
.
001
,
respectively
)
.
High
level
of
TAFI
antigen
in
attack-free
period
of
FMF
disease
shows
ongoing
subclinical
inflammation
and
hypercoagulability
.
Clinicians
should
be
careful
about
thrombosis
even
in
patients
at
clinical
remission
.
Also
,
genetic
tests
must
be
considered
to
predict
clinical
outcome
and
to
reduce
complications
of
FMF
disease
.
Diseases
Validation
Diseases presenting
"high level"
symptom
22q11.2 deletion syndrome
aniridia
cadasil
carcinoma of the gallbladder
cohen syndrome
congenital toxoplasmosis
cutaneous mastocytosis
cystinuria
dedifferentiated liposarcoma
dentinogenesis imperfecta
erdheim-chester disease
erythropoietic protoporphyria
esophageal carcinoma
esophageal squamous cell carcinoma
familial hypocalciuric hypercalcemia
familial mediterranean fever
hodgkin lymphoma, classical
inclusion body myositis
liposarcoma
lymphangioleiomyomatosis
omenn syndrome
oral submucous fibrosis
pyomyositis
scrub typhus
waldenström macroglobulinemia
well-differentiated liposarcoma
werner syndrome
x-linked adrenoleukodystrophy
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom